Hepatitis C treatment – state-of-the-art and prospection
Abstract
The target of the new approach to hepatitis C treatment – so called triple therapy (protease inhibitors additional to peginterferon and ribavirin) – are the viral proteins. The sustained virologic response achieved in 70% patients with genotype 1, however the increasing
of adverse treatment events (in comparison with interferon therapy) was obtained. Therefore, more effective regimens, including the second generation of protease inhibitors (Simeprevir, Daclatasvir, Asunaprevir, Faldaprevir and others), viral proteins NS5A (Daclatasvir,
Ledipasvir) inhibitors and inhibitors of RNA-polymerase NS5B (nucleoside – Sofosbuvir, Mericitabine, and non-nucleoside – in particular, TMC-647055, VX-222, ANA598, IDX-375 and others, that are on different phases of clinical trials). The regimens of the triple therapy, including new drugs of direct antiviral action, and regimens excluded interferon may be implemented in patients with hepatocirrhosis and serious concomitant diseases. Moreover, some new drugs of direct antiviral action are strong inhibitors, irrespective of viral hepatitis C genotype. For patients with poor virologic response by standard regimens, four-component treatment is required. In future, individual-tailored treatment, depend on patients’ peculiarities and/ or viral hepatitis C genotype.
About the Authors
N. P. Blochina
ГКУЗ «Инфекционная клиническая больница №1 Департамента здравоохранения города Москвы»; ГБОУ ВПО «Московский государственный медико-стоматологический университет имени А.И. Евдокимова»
Russian Federation
Russian Federation
N. A. Malyshev
ГКУЗ «Инфекционная клиническая больница №1 Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
E. A. Nurnuchametova
ГКУЗ «Инфекционная клиническая больница №1 Департамента здравоохранения города Москвы»; ФГБУ «НИИ вирусологии им. Д.И. Ивановского» Минздрава России
Russian Federation
Russian Federation
References
1. Asselah T., Marcellin P. Direct acting antivirals for. the treatment of chronic hepatitis C: one pill a day for tomorrow // Liver Int. – 2012. – Vol. 32. – P. 88-102.
2. Bacon B.R., Gordon S.C., Lawitz E. et al. Boceprevir for previously treated chronic HCV genotype 1 infection // N. Engl. J. Med. – 2011. – Vol. 364 – P. 1207-1217.
3. Barreiro P., Vispo E., Poveda E. et al. Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver // Clin. Infect. Dis. – 2013. – Vol. 56. – P. 560-566.
4. De Bruijne J., van de Wetering, de Rooij J. et al. First-in-human study of the pharmacokinetics and antiviral activity of IDX375, a novel nonnucleoside hepatitis C virus polymerase inhibitor // Antimicrob. Agents Chemother. – 2012. – Vol. 56. – N. 8. – P. 4525-4528.
5. Castro C., Amold J.J., Cameron C.E. Incorporation delity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspective // Virus res. – 2005. – Vol. 107. – P. 141-149.
6. Devogelaere B., Berke J.M., Vijgen L. et al. TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage // Antimicrob. Agents Chemother. – 2012. – Vol. 56. – N. 9. – P. 4676-4684.
7. Editors of the Drafting Committee for Hepatitis Management Guidelines: The Japan Society of Hepatology: Guidelines for the management of hepatitis virus infection // Hepatol. Res. – 2013. – Vol. 43. – P. 1-34.
8. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. // Gastroenterology. – 2012. – Vol. 142. – P. 1264-1273.
9. European Association for the Study of the Liver: EASL clinical practice guidelines: management of hepatitis C virus infection // J/ Hepatol – 2011. – Vol. 55. – P. 245-264.
10. Everson G.T, Sims K.D., Rodriguez-Torres M. et al. An interferon-free, ribavirin-free 12-week regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS- 791325 yielded SVR4 of 94% in treatment-naive patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection // 63rd Annual Meeting of the American Association for the Study of Liver Diseases: Program and abstracts. – Boston, 2012. – Abstr. LB-3.
11. De Francesco R., Migliaccio G. Challenges and successes in developing new therapies for hepatitis C // Nature. – 2005. – Vol. 436. – P. 953–960.
12. Gane E.J. et al. Vertex Quad therapy yielded 83-93% SVR with 12 weeks duration of therapy: VX-222/Telaprevir in combination with Peginterferon-Alfa-2a and Ribavirin in treatment-naive genotype 1 HCV patients treated for 12 weeks: Zenith study, SVR12 Interim Analysis // 22nd Conference of the Asian Pacific Association for the Study of the Liver. – Taipei, Taiwan, 2012. – Retrieved from the Internet < URL:http://www.natap.org/2012/APASL/APASL–11.htm>.
13. Gane E.J., Stedman C.A., Hyland R.H. et al. Nucleotide polymerase inhibitor Sofosbuvir plus Ribavirin for hepatitis C // N. Engl. J. Med. – 2013. – Vol. 368. – P. 34-44.
14. Gentile I., Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis // J. Hepatol. – 2010. – Vol. 52. – P. 778.
15. Gentile I., Viola C., Borgia F. et al. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection // Curr. Med. Chem. – 2009. – Vol. 16. – P. 1115-1121.
16. Hezode C. et al. 62nd Annual Meeting of the American Association for the Study of Liver Diseases: Program and abstracts. – San Francisco, 2011. – Abstr. 227.
17. Kanda T., Steele R., Ray R., Ray R.B. Small interfering RNA targeted to hepatitis C virus 5’ nontranslated region exerts potent antiviral effect // J. Virol. – 2007. – Vol. 81. – P. 669-676.
18. Kanda T, Yokosuka O, Omata M. Hepatitis C virus and hepatocellular carcinoma // Biology. – 2013. – Vol. 2. – P. 304-316.
19. Lawitz E., Rodriguez-Torres M., Rustgi V.K. et al. Safety and antiviral activity of ana598 in combination with pegylated interferon alpha2a plus ribavirin in treatment-naive genotype 1 chronic HCV patients // J. Hepatol. – 2010. – Vol. 52 (suppl. 1). – S. 467.
20. Levin J., Poordad F., Lawitz1 E. et al. Interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/- Ribavirin achieve high SVR12 and SVR24 rates in patients with chronic HCV genotype 1b // 23rd Conference of the Asian Pacific Association for the Study of the Liver. – Singapore, 2013 http://www.natap.org/2013/HCV/060713_02.htm
21. Lin C., Kwong A.D., Perni R.B. Discovery and development of VX950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease // Infect. Disord. Drug Targets. – 2006. – Vol. 6. – P. 3-16.
22. Lönnroth K, Raviglione M. Global epidemiology of tuberculosis: prospects for control // Semin. Respir. Crit. Care Med. – 2008. – Vol. 29. – N. 5. – P. 481-491.
23. Lok A.S., Gardiner D.F., Lawitz E. Preliminary study of two antiviral agents for hepatitis C genotype 1 // N. Engl. J. Med. – 2012. – Vol. 366. – P. 216-224.
24. Nakamoto S., Kanda T., Imazeki F. et al. Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients // Scand. J. Gastroenterol. – 2011. – Vol. 46. – P. 955-961.
25. Osinusi A., Heytens L., Lee Y. et al. High efficacy of GS-7977 in combination with low or full dose ribavirin for 24 weeks in difficult to treat HCV infected genotype 1 patients // 63rd Annual Meeting of the American Association for the Study of Liver Diseases: Program and abstracts. – Boston, 2012. – Abstr. LB-4.
26. Penney M.S., De Souza C., Seepersaud S. et al. All IL28B genotypes have high SVR rates in patients treated with VX-222 in combination with Telaprevir/ Peginterferon/Ribavirin in the ZENITH Study // 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012). – Barcelona, 2012. – Abstr. 1203.
27. Poordad F., Dieterich D. J. Treating hepatitis C: current standard of care and emerging directacting antiviral agents // Viral Hepat. – 2012. – Vol. 19. – P. 449-464.
28. Poordad F., McCone J. Jr., Bacon B.R. et al. Boceprevir for untreated chronic HCV genotype 1 infection // N. Engl. J. Med. – 2011. – Vol. 364. – P. 1195-1206.
29. Rodriguez-Torres M., Lawitz E., Conway B. et al. Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 treatmentnaïve genotype 1 HCVinfected patients // J. Hepatol. – 2010. – Vol. 52 (suppl. 1). – S. 14.
30. Sarin S.K., Kumar M. Natural history of HCV infection // Hepatol. Int. – 2012. – Vol. 6. – P. 684-694.
31. Sarrazin C., Kieffer T.L., Bartels D. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir // Gastroenterology. – 2007. – Vol. 132. – P. 1767-1777.
32. Schaefer E., Chung R. Anti-hepatitis C virus drugs in development // Gastroenterology. – 2012. – Vol. 142. – P. 1340–1350.
33. Sulkowski M., Gardiner D., Lawitz E., et al. Potent viral suppression with all-oral combination of Daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +/- Ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3 // 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012). – Barcelona, 2012. – Abstr. 1422.
34. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M. et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5a inhibitor) plus sofosbuvir (nucleotide NS5b inhibitor) with or without ribavirin, in treatmentnaive patients chronically infected with HCV GT 1, 2, or 3 // 63rd Annual Meeting of the American Association for the Study of Liver Diseases: Program and abstracts. – Boston, 2012. – Abstr. LB-2.
35. Summa V., Ludmerer S.W., McCauley J.A. et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants // Antimicrob. Agents Chemother. – 2012. – Vol. 56. – P. 4161-4167.
36. Tosone G., Borgia G., Gentile I. et al. A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided? // Acta Diabetol. – .2007. – Vol. 44. – P. 167-169.
37. Tsuda N., Yuki N., Mochizuki K. et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy // J. Med. Virol. – 2004. – Vol. 74. – P. 406-413.
38. Welsch C., Jesudian A., Zeuzem S. et al. New directacting antiviral agents for the treatment of hepatitis C virus infection and perspectives // Gut. – 2012. – Vol. 61 (Suppl 1). – P. i36–i46.
39. Yew W.W/, Leung C.C. Antituberculosis drugs and hepatotoxicity // Respirology. – 2006. – Vol. 11. – P. 699–707.
40. Zeuzem S., Berg T., Gane E. et al. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ribavirin treatment: final SVR24 results of the aspire trial // J. Hepatol. – 2012. – Vol. 56 (Suppl 2). – S1-S2.
41. Zeuzem S., Buggisch P., Agarwal K. et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C // Hepatology. – 2012. – Vol. 55. – P. 749–758.
Review
For citations:
Blochina N.P., Malyshev N.A., Nurnuchametova E.A. Hepatitis C treatment – state-of-the-art and prospection. Tuberculosis and socially significant diseases. 2013;(1):73-78. (In Russ.)
Views:
33
Email this article 